Medication info
Sevisartan Tablets 10/40 mg

Sevisartan Tablets 10/40 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Orotate›13.82mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Reddish-brown round film-coated tablet
Packaging
30 tablets/PTP
Approval status
Active

MFDS item code 201405045 · Approved 2014.10.30 · Insurance code 642507130

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not take this medicine under Precautions for Use.) ∘Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. In older adults, blood pressure should be monitored closely and more frequently.
Child dose
∘Children: Safety and efficacy have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine or Olmesartan Medoxomil is used for patients with essential hypertension and is utilized to enhance therapeutic effects when blood pressure is not adequately controlled by monotherapy. These medications lower blood pressure by dilating blood vessels and reducing cardiovascular burden, thereby decreasing the risk of complications. As such, they assist in the management of essential hypertension and blood pressure control, contributing to the improvement of patient health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not take this medicine under Precautions for Use.) ∘Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. In older adults, blood pressure should be monitored closely and more frequently.

Child dose

∘Children: Safety and efficacy have not been established in pediatric patients under 18 years of age.

Precautions

This medication may cause serious harm or death to the fetus and newborn if taken during the second and third trimester of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be taken by those who are allergic to this drug or other drugs in a similar class, by those who are pregnant or nursing, by those suffering from severe liver diseases or aortic stenosis, by individuals experiencing biliary obstruction, those undergoing kidney dialysis, those in a state of shock, specific diabetic patients, and those with severe renal impairment. Individuals with reduced body fluids or sodium may experience hypotension when taking this drug; thus, careful monitoring of their condition is advised when starting therapy. There is a risk of sudden vasodilation and resultant rapid blood pressure drop, so patients with heart conditions such as aortic stenosis should exercise particular caution. Heart disease or heart failure patients may experience worsening symptoms upon taking this drug; thus, consultation with healthcare professionals is advised for careful usage. Patients with impaired kidney function should undergo regular testing, as this medication may affect kidney performance. Those with decreased liver function should use this medication cautiously, as its metabolism may be slowed. Various side effects may occur, including dizziness, headache, hypotension, cough, digestive disorders, rash, edema, and more. Patients should particularly monitor potassium levels, as they may increase; caution is needed when combining this drug with foods or medications high in potassium. This drug should not be taken during pregnancy, and if pregnancy is planned or confirmed, consultation with healthcare professionals is essential. If nursing, it is recommended to cease breastfeeding or to discontinue the medication, as it may be transferred in breast milk. The safety and efficacy of this medication have not been established in children under 18 years of age. Elderly patients should start at a low dose, considering potential decreases in liver, kidney, and heart function and other illnesses. Overdose may result in severe hypotension and vascular dilation, requiring prompt medical attention. This medication should be stored away from direct sunlight and moisture, out of reach of children, and it is advised not to transfer it into another container.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory loss
  • syncope
Show 82 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • increased urinary frequency
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • weakness
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening cerebral infarction
  • gum bleeding
  • positional dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • jaundice
  • elevated liver enzymes
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture; therefore, it must be stored in a tightly sealed container. It is important to maintain storage temperatures between 1 and 30 degrees Celsius to keep the drug's efficacy intact and to prevent deterioration.

Appearance and packaging

Appearance

Reddish-brown round film-coated tablet

Package unit

30 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.